<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03382301</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0823</org_study_id>
    <nct_id>NCT03382301</nct_id>
  </id_info>
  <brief_title>Ciclosporin A Preconditioning for Renal Artery Stenosis</brief_title>
  <acronym>CicloSAAR</acronym>
  <official_title>Impact of a Ciclosporin A Preconditioning for Prevention of Ischemia-reperfusion Injury After Renal Artery Stenosis Dilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal artery stenosis is one the leading cause of secondary hypertension. Previous randomized&#xD;
      controlled trials in humans have failed to demonstrate an improvement of renal function after&#xD;
      stenosis dilation, probably because of a selection bias with more severe patients being&#xD;
      excluded from randomization. Renal ischemia-reperfusion injuries have also not been taken&#xD;
      into account. Indeed, reperfusion leads to a rapid renal blood flow recovery associated with&#xD;
      renal ischemia-reperfusion injuries.&#xD;
&#xD;
      Mitochondrial permeability transition pore (mPTP) is a key player in the occurrence of&#xD;
      ischemia reperfusion injuries because its opening leads to mitochondria leakage and cell&#xD;
      death. However, preconditioning whether pharmacological or ischemic can prevent mPTP opening&#xD;
      and protect cells. Ciclosporin A can prolong mPTP closing during reperfusion and reduce renal&#xD;
      and cardiac tissular lesions. Another mPTP blocker (Bendavia) has been associated with an&#xD;
      improvement of renal blood flow (RBF) and glomerular filtration rate (GFR) after renal artery&#xD;
      stenosis dilation at 6 weeks in pigs. Based on a recent study, dilation overall benefit could&#xD;
      be secondary to an improvement of the contralateral kidney GFR and tissue oxygen content,&#xD;
      requiring a single kidney evaluation of those renal functional parameters. The investigators&#xD;
      previously demonstrated that dose and timing of ciclosporin A preconditioning is key to&#xD;
      protect kidneys from ischemia-reperfusion injuries. Previous controlled trials that failed to&#xD;
      demonstrate a benefit of ciclosporin A conditioning have used post conditioning on necrotic&#xD;
      cells. Considering kidney ischemia-reperfusion injuries, preconditioning have led to more&#xD;
      encouraging results compared to ciclosporin A post conditioning in animals. Therefore the&#xD;
      investigators aim to conduct the first clinical study of ciclosporin A preconditioning for&#xD;
      prevention of kidney ischemia-reperfusion injuries after renal artery stenosis dilation.&#xD;
&#xD;
      Using renal functional imaging and the new PET-MRI (Positron Emission Tomography-Magnetic&#xD;
      Resonance Imaging) combined device, the investigators will evaluate kidney perfusion,&#xD;
      oxidative metabolism, glomerular filtration rate and oxygen content before and 3 months after&#xD;
      renal artery stenosis dilation with or without a ciclosporin A preconditioning.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in relative increase (baseline and 3 months after) of global renal perfusion between the two groups</measure>
    <time_frame>3 months after renal artery stenosis dilation</time_frame>
    <description>Global renal perfusion is assessed by 15O labeled water PET (Positron Emission Tomography) imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in the relative increase (baseline and 3 months after) of global renal oxidative metabolism between the two groups</measure>
    <time_frame>3 months after renal artery stenosis dilation</time_frame>
    <description>Global renal oxidative metabolism is assessed by 11C labeled acetate PET (Positron Emission Tomography) imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the relative increase (baseline and 3 months after) of global renal oxygen content between the two groups</measure>
    <time_frame>3 months after renal artery stenosis dilation</time_frame>
    <description>Global renal oxygen content is assessed by BOLD MRI (Blood-Oxygen-Level Dependent Magnetic Resonance Imaging)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the relative increase (baseline and 3 months after) of global glomerular filtration rate between the two groups</measure>
    <time_frame>3 months after renal artery stenosis dilation</time_frame>
    <description>Global glomerular filtration rate is assessed by Iohexol measured clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the relative increase (baseline and 3 months after) of single-kidney perfusion (ischemic versus contralateral kidney) between the two groups</measure>
    <time_frame>3 months after renal artery stenosis dilation</time_frame>
    <description>Kidney perfusion is assessed by 15O labeled water PET (Positron Emission Tomography) imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Renal Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Ciclosporin A preconditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciclosporin A preconditioning before renal artery stenosis dilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl preconditioning</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclosporin A preconditioning before renal artery stenosis dilation</intervention_name>
    <description>Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation</description>
    <arm_group_label>Ciclosporin A preconditioning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl preconditioning before renal artery stenosis dilation</intervention_name>
    <description>NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation</description>
    <arm_group_label>NaCl preconditioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 50 years of age&#xD;
&#xD;
          -  For women : only menopausal women&#xD;
&#xD;
          -  Estimated Glomerular filtration rate ≥ 25 mL/min/1.73m2&#xD;
&#xD;
          -  Renal artery stenosis with ≥ 70 % caliber reduction (Doppler or scanner or MRI)&#xD;
&#xD;
          -  No controlateral stenosis&#xD;
&#xD;
          -  Kidney size ≥ 7 cm&#xD;
&#xD;
          -  Only atheromatous renal artery stenosis&#xD;
&#xD;
          -  Resistant hypertension and/or rapid loss of kidney function and/or flash pulmonary&#xD;
             edema&#xD;
&#xD;
          -  Collective decision of dilation after a multidisciplinary meeting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inclusion in another study&#xD;
&#xD;
          -  Protected adults&#xD;
&#xD;
          -  Person without a social security coverage&#xD;
&#xD;
          -  Imprisoned person&#xD;
&#xD;
          -  Systolic blood pressure &gt;180 mmHg and/or diastolic blood pressure &gt; 110 mmHg&#xD;
&#xD;
          -  Non atheromatous renal artery stenosis&#xD;
&#xD;
          -  Single kidney&#xD;
&#xD;
          -  Multiple myeloma&#xD;
&#xD;
          -  Iodine contrast agents allergy&#xD;
&#xD;
          -  Ciclosporin A hypersensibility&#xD;
&#xD;
          -  Severe other medical conditions that could be exacerbated by Iodine injection (cancer,&#xD;
             lymphoma, active Hepatitis B, active Hepatitis C, uncontrolled HIV)&#xD;
&#xD;
          -  Previous radiation exposure (above 20 mSv (millisievert) in the last 6 months before&#xD;
             inclusion)&#xD;
&#xD;
          -  MRI contra indications (MRI incompatible pacemaker or insulin pomp, metal clip, MRI&#xD;
             incompatible cardiac valve, dental brace, claustrophobia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandrine LEMOINE, MD</last_name>
    <phone>472 110 263</phone>
    <phone_ext>+33</phone_ext>
    <email>Sandrine.lemoine01@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabrielle Laetitia NORMAND, MD</last_name>
    <phone>472 110 263</phone>
    <phone_ext>+33</phone_ext>
    <email>laetitia.normand@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Exploration Fonctionnelle Rénale, Hôpital Edouard Herriot, Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine LEMOINE, MD</last_name>
      <phone>472 110 263</phone>
      <phone_ext>+33</phone_ext>
      <email>Sandrine.lemoine01@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Gabrielle Laetitia NORMAND, MD</last_name>
      <phone>472 110 263</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.normand@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sandrine LEMOINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2017</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemia reperfusion injuries</keyword>
  <keyword>Renal artery stenosis</keyword>
  <keyword>Renal functional imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Artery Obstruction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

